Linezolid resistant Staphylococcus aureus

Pavani Gandham

Abstract


Linezolid is the only antibiotic available as an oral formulation for resistant staphylococcal infections. It is effective in skin & soft tissue infections, nosocomial pneumonias including VAP, infective endocarditis and MRSA meningitis. It is also effective in the eradication of both nasal & throat colonization of MRSA. Its high bioavailability and post antibiotic effect, ease of switching to oral therapy during its use and the fact that it can be used in patients of all ages, also in patients with liver disease and poor kidney function and its increased effectiveness over glycopeptides makes this drug a precious drug in the treatment of resistant staphylococcal infections. Linezolid resistance in staphylococcus is defined as a linezolid MIC of ≥8 mg/L. Reported Linezolid resistance in India and elsewhere is 2-20%.There is clonal dissemination of Linezolid Resistant Staphylococcus aureus (LRSA) within or across health care settings which demands continuous surveillance to determine the emergent risk of resistance strains and to establish guidelines for appropriate use. Clinical laboratories should confirm any LRSA preferably by a second method, prior to using linezolid for serious infections. Effective surveillance, more judicious use of this antibiotic, avoiding linezolid usage for empiric therapy in hospital acquired staphylococcus infections, optimization of the pharmacological parameters of the antibiotics in specific clinical situation, decreasing bacterial load by timely surgical debridement or drainage of collections, use of combination therapies would prevent the emergence of resistance to linezolid in staphylococcus aureus.

 


Keywords


Linezolid, Staphylococcus aureus, Linezolid resistant staphylococcus aureus

Full Text:

PDF

References


Serag-Eldin A, Amany T, Noha G. Clinical and microbiological effect of linezolid on methicillin-resistant Staphylococcus aureus colonization in healthcare workers in Egypt. Middle-East J Sci Res. 2013;15(10):1440-9.

Lakshmi S, Peerapur BV, Smitha B. Detection of in-vitro activity of linezolid in methicillin resistant Staphylococcus aureus infections by E-test. JKIMSU. 2012;1(2):72-5.

Melzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus bacteremias. Clin Infect Dis. 2000;31(1):208-9.

Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 1998;42(12):3251-5.

Ball AT, Xu Y, Sanchez RJ. Non-adherence to oral linizolid after hospitalization: a retrospective claims analysis of the incidence and consequence of claim reversals. Clin Ther. 2010;32:2246-55.

Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353(21):2305-6.

Barnhill AE, Brewer MT, Carlson SA. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob Agents Chemother. 2012;56(8):4046-51.

Grau S, Rubio-Terres C. Pharmacoeconomics of linezolid. Expert Opin Pharmacother. 2008;9(6):987-1000.

Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram positive bacterial infections. Clin Infect Dis. 2000;30:1246-51.

Laurie Barclay. Outbreak of MRSA with linezolid resistance documented in Spain. Adv Infect Dis. 2010;1:3-6.

Wilson AP, Cepeda JA, Hayman S. In vitro susceptibility of gram positive pathogens to linezolid and teichplanin and effect on outcome in critically ill patients. J Antimicrob Chemother. 2006;58(2):470-3.

Hamdan-Partida A, Sainz-Espunes A, Bustos-Martinez J. Characterisation and persistence of Staphylococcus aureus strains isolated from the anterior nares and throats of healthy carriers in a Mexican community. J Clin Microbiol. 2010;48(5):1701-5.

Bing G, Theodoros K, Sotirios T. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2012;69(1):1-37.

Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharmaceut Design. 1996;2(2):175-94.

Garcia M, Juan J, Elvira B. Resistance to linezolid is mediated bu the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010;50(6):821-5.

Tsiodras S, Gold HS, Sakoulas G. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-8.

Rajaduraipandi K, Mani KR, Panneerselvam K. Prevalence and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus: a multicenter study. Indian J Med Microbiol. 2006;24:34-8.

Norma V, Juan Carlos V, Gerado EV. Resistance to linezolid of methicillin-resistant Staphylococcus aureus and Enterococcus with high level resistance to aminoglycosides at a third level pediatric hospital. Bol Med Hosp Infant Mex. 2010;67:17-24.

Harcharan Singh, Meena Atray, Pankaj Kumar Modi. Antibiotic susceptibility pattern of methicillin resistant Staphylococcus aureus in tertiary care center at Southern Rajasthan. IJPSR. 2014;5(2):607-11.

Sarma JB, Ahmed GU. Characterisation of methicillin resistant S. aureus strains and risk factors for acquisition in a teaching hospital in northeast India. Indian J Med Microbiol. 2010;28(2):127-9.

Besier S, Ludwig A, Zander J. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs and cross-resistances. Antimicrob Agents Chemother. 2008;52(4):1570-2.

Sanchez Garcia M, Dela Torre MA, Morales G. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA. 2010;303:2260-4.

Padilla B, Bunsow E, Cercenado E. Eradication of an outbreak of linezolid-resistant methicillin-resistant Staphylococcus aureus in a post-surgical intensive care unit. Am Soc Microbiol. 2011;238(1):1.

Wilson P, Andrews JA, Charlesworth R. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 2003;51:186-8.

Arias CA, Vallejo M, Reyes J. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23 SrRNA methyl transferase. J Clin Microbiol. 2008;46(3):892-6.

Sebastiaan J, Vance G. Fowler. Is it time to replace Vancomycin in the treatment of Staphylococcus aureus infections? Clin Infect Dis. 2013;56(12):1779-88.

Tenovar FC, Williams PP, Stocker S. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J Clin Microbiol. 2007;45:2917-22.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. In: CLS, eds. 22nd Informational Supplement. Wayne, PA, USA: CLSI; 2012: M 100-S22.

European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MIC s and zone diameters, 2009. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.0_20091221.pdf.

Esbetan N, Barbara EM, Cesar AA. Resistance or decreased susceptibility to glycopeptides, daptomycin and linezolid in methicillin-resistant Staphylococcus aureus. Curr Opin Pharmacol. 2010;10:1-6.